-
Mylan's Q1 sales increase by 12%; judge dismisses case against FDA
PITTSBURGH — Sales at generic drug maker Mylan increased by 12% during first quarter 2011, compared with first quarter 2010, the company said Tuesday.
Sales for the three months ended March 31 were $1.45 billion, compared with $1.29 billion during the same period a year ago. Profits, meanwhile, were $104.2 million, compared with $61.1 million in first quarter 2010.
-
BioScrip reports turnaround in Q1
ELMSFORD, N.Y. — First quarter 2011 sales at specialty pharmacy provider BioScrip increased by 31.1% over first quarter 2010. The company also showed a profit, compared with losses during the same period last year, according to financial results released Tuesday.
The company had sales of $439.3 million, compared with $335.1 million in first quarter 2010, while profits were $2.9 million, compared with losses of $7.2 million a year ago.